Lung Adenocarcinoma of Never Smokers and Smokers Harbor Differential Regions of Genetic Alteration and Exhibit Different Levels of Genomic Instability by Thu, Kelsie L. et al.
 
Lung Adenocarcinoma of Never Smokers and Smokers Harbor
Differential Regions of Genetic Alteration and Exhibit Different
Levels of Genomic Instability
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Thu, Kelsie L., Emily A. Vucic, Raj Chari, Wei Zhang, William
W. Lockwood, John C. English, Rong Fu, et al. 2012. Lung
adenocarcinoma of never smokers and smokers harbor differential
regions of genetic alteration and exhibit different levels of
genomic instability. PLoS ONE 7(3): e33003.
Published Version doi:10.1371/journal.pone.0033003
Accessed February 19, 2015 9:56:14 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10304422
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAALung Adenocarcinoma of Never Smokers and Smokers
Harbor Differential Regions of Genetic Alteration and
Exhibit Different Levels of Genomic Instability
Kelsie L. Thu
1*, Emily A. Vucic
1, Raj Chari
1,2, Wei Zhang
3, William W. Lockwood
1,4, John C. English
5,
Rong Fu
6, Pei Wang
6, Ziding Feng
6, Calum E. MacAulay
1, Adi F. Gazdar
3, Stephen Lam
1, Wan L. Lam
1
1Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada, 2Department of Genetics, Harvard Medical School,
Boston, Massachusetts, United States of America, 3Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas,
United States of America, 4Cancer Genetics Branch National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of
America, 5Department of Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada, 6Division of Public Health Sciences, Fred Hutchinson Cancer
Research Centre, Seattle, Washington, United States of America
Abstract
Recent evidence suggests that the observed clinical distinctions between lung tumors in smokers and never smokers (NS)
extend beyond specific gene mutations, such as EGFR, EML4-ALK, and KRAS, some of which have been translated into
targeted therapies. However, the molecular alterations identified thus far cannot explain all of the clinical and biological
disparities observed in lung tumors of NS and smokers. To this end, we performed an unbiased genome-wide, comparative
study to identify novel genomic aberrations that differ between smokers and NS. High resolution whole genome DNA
copy number profiling of 69 lung adenocarcinomas from smokers (n=39) and NS (n=30) revealed both global and regional
disparities in the tumor genomes of these two groups. We found that NS lung tumors had a greater proportion of their
genomes altered than those of smokers. Moreover, copy number gains on chromosomes 5q, 7p, and 16p occurred more
frequently in NS. We validated our findings in two independently generated public datasets. Our findings provide a novel
line of evidence distinguishing genetic differences between smoker and NS lung tumors, namely, that the extent of
segmental genomic alterations is greater in NS tumors. Collectively, our findings provide evidence that these lung tumors
are globally and genetically different, which implies they are likely driven by distinct molecular mechanisms.
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Introduction
While the majority of lung cancer cases can be attributed to
tobacco smoking, up to one quarter of lung cancers arise in never
smokers (NS) [1]. When considered its own disease, lung cancer in
NS is the seventh leading cause of cancer death worldwide [2].
Studies have revealed that NS lung tumors are characterized by
specific clinical and genetic features [2,3,4,5,6,7,8,9]. NS lung
cancers are more strongly associated with female gender, East
Asian ethnicity and adenocarcinoma histology [2]. Molecularly,
NS tumors have a significantly higher frequency of EGFR
mutations and EML4-ALK translocations, findings that have been
clinically translated for selection of targeted therapies [2,10,11].
Interestingly, it was recently discovered that mitochondrial DNA
(mtDNA) genomes of NS harbored more alterations than those of
smokers [9]. While collectively these findings provide evidence
supporting the notion that NS lung tumors are driven by distinct
genetic mechanisms, they cannot explain all of the clinical
disparities observed in lung tumors of smokers and NS. They do
however, emphasize the need to identify additional genomic
aberrations that may underlie observed differences in tumor
biology and provide a rationale for undertaking a global scale
comparative genomic study of lung tumors arising in smokers and
NS.
Previous studies have focused on locus specific genetic features
or have been limited by the use of low resolution technologies
lacking whole genome coverage, comparison between NS and
smokers, and/or validation in external cohorts [5,6,7,8,12,13,14].
Therefore, to determine whether smoker and NS lung tumors are
distinct on a global level, an unbiased genome-wide survey and
direct comparison is warranted.
Copy number alterations (CNAs) are known contributors to
tumorigenesis, and different cancer subtypes display distinct copy
number profiles which are associated with distinct phenotypic and
clinical features [15]. Thus, we hypothesized that lung tumor
genomes of smokers and NS would exhibit disparate patterns of
DNA CNAs throughout the genome that may drive the distinct
clinical presentation of these tumor types. Towards this aim, we
performed a global comparative analysis of copy number changes
in lung cancers from smokers and NS. Since most lung cancers in
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33003NS are adenocarcinomas, we restricted our study to this type of
lung cancer. We identified unique genomic features and NS-
specific CNAs that were validated in two additional cohorts. These
data may provide insight into the molecular basis for the
differential tumor behaviors observed in the clinic.
Methods
Ethics statement
All tissues were collected from the Tumor Tissue Repository of
the British Columbia Cancer Agency under informed, written
patient consent and with approval from the University of British
Columbia - BC Cancer Agency Research Ethics Board.
Sample accrual
Both tumor and adjacent non-malignant lung tissues were
accrued for 69 treatment naive lung adenocarcinoma (AC)
patients undergoing surgical resection with curative intent (BCCA
tumors). These included 39 smokers (current smokers (CS) at the
time of diagnosis) and 30 NS (patients who had smoked fewer than
100 cigarettes in their lifetime). Tissues were fresh-frozen and
underwent pathological review to confirm AC histology and
absence of cancer cells in the adjacent non-malignant lung tissue.
DNA was extracted using standard phenol:chloroform procedures.
Each tumor was microdissected with guidance of a pathologist
(JCE or AFG) to ensure .70% tumor cell content.
EGFR and KRAS mutation screening
Genomic DNA from each tumor was sequenced to determine
KRAS and EGFR mutation status by PCR amplification and
product sequencing. Exons 19 and 21 and exon 2 were screened in
EGFR and KRAS, respectively. PCR was performed on 50–100 ng
of DNA in 25 mL reactions using the Applied Biosystems
GeneAmp PCR System 9700. Applied Biosystems BigDye
Terminator v3.1 cycle sequencing kit and capillary instrumenta-
tion were used to sequence PCR products. Primer sequences and
PCR conditions are supplied in Table S1. A Fisher’s exact test was
used to assess associations of EGFR and KRAS mutation with
smoking status. A p-value,0.05 was considered significant. The
relationships between clinical variables (stage, gender, age,
smoking) and EGFR and KRAS mutation status were assessed
using Pearson correlation.
SNP array processing
Genomic DNA from tumor and matched non-malignant lung
tissues were hybridized to Affymetrix SNP 6.0 arrays according to
the manufacturer’s instructions. Raw CEL probe intensity files
were processed using Partek Genomics Suite Software (Partek
Incorporated, Missouri). Probe sequence, fragment length, GC
content and background adjustments were applied to correct for
biases in signal intensities. Copy number profiles were generated
following the Copy Number, Paired Analysis Workflow such that
matched non-malignant profiles were used as a copy number
baseline for each respective tumor. Genomic segmentation was
applied with stringent significance thresholds to identify segmental
regions of CNA (gain and loss) using the following parameters:
signal to noise .0.3, minimum of 50 markers per segment, p-value
threshold of 10
27 for the statistical difference between intensities of
adjacent segments, and p-value threshold of 10
27 for significance
of deviation of intensities in tumor tissue from intensities in non-
malignant lung. This stringency enabled us to confidently
distinguish altered genomic segments from technical noise.
Identified segments were merged using a 1 Mbp window to
combine adjacent regions of copy gain or loss. All genomic
mapping was based on the March 2006, hg18 genome build. The
genomic coordinates for RefSeq genes (hg18) were obtained from
the UCSC genome browser [16]. SNP array data for the BCCA
tumors is in compliance with the MIAME guidelines and has been
deposited in the Gene Expression Omnibus (GEO accession ID
pending).
Genome comparisons
For each tumor the sum of base pairs encompassed by CNAs
(both gains and losses) was used to calculate the proportion of
genome altered (PGA) for each tumor. Differences in PGA
between tumor genomes were investigated using a two-tailed,
Student’s t-test assuming unequal variance. P-values,0.05 were
considered significant. Tumors with PGAs in the fifth and 95
th
percentiles were excluded to reduce the effects of outliers. A
multifactor ANOVA was performed in R to assess the contribu-
tions of clinical (stage, gender, age, race, and smoking status) and
genetic (EGFR and KRAS mutation status) variables to the
observed PGA.
Segmental alterations identified in each tumor were parsed into
typed copy numbers for each SNP array element, such that every
array probe was scored as 1 (copy gain), 0 (copy neutral), or 21
(copy loss). Probes with similar copy number states within
individual tumors were then collapsed into genomic regions across
all tumor samples. The frequency of DNA gains, DNA losses, and
neutral copy number were compared in smoker and NS tumor
genomes using a Fisher’s Exact test with a p-value,0.05
considered significant. The Fisher’s Exact test was performed in
R using a 362 contingency table generating a p-value for each
genomic region [17]. Significant regions within 1 Mbp of each
other and with the same copy number status were merged into
single regions. Differentially altered regions had to have at least
15% frequency difference between smokers and NS and a
frequency of at least 15% in one group if both groups showed
alteration to be reported here. ResCalc was used to determine the
functional resolution of the SNP array data given the segmentation
parameters we applied (139 kbp). Thus, we only considered
differentially altered regions satisfying this size threshold [18].
The GISTIC (Genomic Identification of Significant Targets in
Cancer) algorithm was used to investigate high-level DNA
alterations (defined as frequent alterations with high magnitude
changes in some samples) in smokers and NS in the BCCA cohort
as it had the highest resolution copy number data for mapping
focal genomic events [19]. We performed GISTIC analysis on the
segmental alteration data with the following parameters: amplifi-
cation threshold=0.848, deletion threshold=0.737, join segment
size=50, q-value threshold of 0.05, and hg18 genome build.
Regions identified in smokers and NS were then compared to
determine regions of overlap and regions of difference based on
the region limit boundaries defined by GISTIC.
Analysis of validation datasets
Publically available microarray data with accompanying
smoking status annotation was accessed to compare findings from
the BCCA tumors with external cohorts. Normalized, lung
adenocarcinoma Agilent 4644 k array comparative genomic
hybridization (aCGH) data generated by the Memorial Sloan
Kettering Cancer Centre (MSKCC) was obtained from http://
cbio.mskcc.org/Public/lung_array_data/ [20]. The MSKCC
dataset was comprised of 25 current smokers and 41 NS. Copy
number profiles were generated using the segmentation algorithm,
FACADE with default parameters and a baseline distribution of
10 kbp [21]. EGFR and KRAS mutation data were also available
for these tumors from the same source. Affymetrix SNP 250 K
Lung Cancer Differs in Smokers and Never Smokers
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Phenotypes from the Tumor Sequencing Project (TSP) were also
accessed (Study Accession: Study Accession: phs000144.v1.p1).
Array data for 72 current smoker and 37 NS lung adenocarcinoma
and matched non-malignant tissues were processed in Partek with
the same normalization and segmentation parameters as the
BCCA tumors, except for using a 20 marker minimum for
defining segments due to lower array density. PGA was calculated
for each tumor in the MSKCC and TSP datasets. A Student’s t-
test was used to compare PGA in smoker and NS tumors with a p-
value,0.05 considered significant.
Differentially altered regions in smokers and NS were identified
in the MSKCC and TSP datasets applying the same strategy as
that for the BCCA tumors. Minimal common regions (MCRs) of
overlap for regions differentially altered in the same direction in all
three datasets were mapped. Correlations between the MCRs
identified were investigated in the BCCA tumors using a Pearson
correlation. A multifactor ANOVA was also performed to assess
relationships between each of the six MCRs discovered and the
clinical and genetic variables discussed above in the BCCA tumors
(stage, gender, age, smoking status, race, and EGFR and KRAS
mutation status).
Results
Patient demographics
Lung adenocarcinoma and matched non-malignant tissue
specimens were collected from 69 patients, including 39 smokers
and 30 NS (Table 1). Collectively, smoker and NS patients for this
comparative study were well matched for age, gender and stage of
disease; however, ethnic differences existed between smokers and
NS. Consistent with trends of higher incidence of lung cancer in
NS among Asians compared to Caucasians, our NS cohort was
significantly enriched for Asian patients (Fisher’s Exact test,
p=1.3610
28), while our smoker cohort was enriched for
Caucasian patients. One smoker sample was from a Native
American patient.
EGFR and KRAS mutations segregate with smoking status
Consistent with reported literature, mutation rates for EGFR
and KRAS were associated with smoking status, confirming the
accuracy of smoking history classifications. EGFR mutations (exons
19 and 21) were more frequent in NS (17/30 NS versus 1/39
smokers, Fisher’s Exact test, p=2.8610
27) while KRAS mutations
were more frequent in smokers (3/30 NS versus 24/39 smokers,
Fisher’s Exact test, p=1.4610
25) (Figure 1a). Tumors arising in
Asian tumors had significantly more EGFR mutations than those
arising in Caucasians (15/23 Asian versus 3/45 Caucasian,
Fisher’s Exact test, p=5.7610
27) while Caucasians had signifi-
cantly more KRAS mutations than Asians (2/23 Asian versus 25/
45 Caucasian, Fisher’s Exact test, p=1.8610
24). There was no
difference in mutation rates in females compared to males. A
Pearson correlation analysis confirmed these associations (Table
S2). EGFR mutations were negatively correlated with smokers
(Pearson’s r=20.61) while KRAS mutations were positively
correlated with smokers (Pearson’s r=0.52). EGFR mutations
were also positively correlated with Asian ethnicity (Pearson’s
r=0.63) and negatively correlated with KRAS mutations (Pearson’s
r=20.48). Smoking status was also correlated with race (Pearson’s
r=20.68) as our NS cohort was predominantly comprised of
Asians.
EGFR and KRAS mutation data was also available for the
MSKCC lung adenocarcinoma tumors; consistent with the BCCA
tumors, EGFR mutations were more prevalent in NS (23/41 NS
versus 0/25 smokers, Fisher’s Exact test, p=6.3610
27) and KRAS
mutations were more prevalent in smokers (5/41 NS versus 8/25
smokers, Fisher’s Exact test, p=0.06) (Figure 1b). There were no
significant associations between EGFR or KRAS mutations and
gender in the MSKCC dataset, and ethnic information was not
available for analysis. In both the BCCA tumors and the MSKCC
tumors, EGFR and KRAS mutations were mutually exclusive.
Given the consistency of this data with the literature, we concluded
that smoking histories for the BCCA and MSKCC lung tumors
were accurate, ensuring we had appropriate samples to perform a
smoker versus NS comparison.
NS lung tumors have greater fractions of the genome
encompassed by CNAs
Copy number profiles were generated for each BCCA lung
tumor by performing genomic segmentation with stringent
significance thresholds to ensure alterations called were non-
random genetic events. All CNAs identified were somatic events as
opposed to germline variants, as each profile was generated using
matched non-malignant lung tissue as a reference. The frequency
of CNAs throughout the genome (calculated using a moving
average window of 500 SNP array probes) for the 39 smokers and
30 NS is depicted in Figure 2. Upon plotting the frequencies of
alteration at each locus in the genome, we noted that the
frequencies appeared to differ between smokers and NS, despite
the similar distribution of CNAs throughout the genome (Table
S3). To quantitatively assess this observation, we calculated the
fraction of each tumor genome that was encompassed by CNAs
and termed this measure Proportion of Genome Altered (PGA).
Table 1. Demographic data for lung adenocarcinoma tumors
sampled.
Demographic Smokers Never Smokers
Total 39 30
Gender Male 11 7
Female 28 23
Age Range 45–78 39–86
Average 64 70
Ethnicity* Asian 2 21
Caucasian 36 9
First Nations 1 0
Stage IA 12 8
IB 12 9
IIA 2 1
IIB 7 7
IIIA 5 4
IIIB 0 1
IV 1 0
Pack Years** Range 2–120 0
Average 50 0
*The proportion of individuals of Asian descent in our NS smoker cohort was
significantly greater than that of smokers. However, a recent study investigating
genomic differences in Western European versus East-Asian lung
adenocarcinomas reported no difference in PGA [6]. Nonetheless, our validation
cohorts from MSKCC and TSP were from geographically distant research
centers, whose patient demographics (including race) likely differ from our own.
**One pack year is defined as smoking one package of cigarettes every day for
one year.
doi:10.1371/journal.pone.0033003.t001
Lung Cancer Differs in Smokers and Never Smokers
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33003Comparison of PGA between smokers and NS revealed that
indeed, NS have a greater PGA than smokers (Student’s t-test,
p=0.03) (Figure 1c, Table 2). Although there was no significant
difference between the fraction of genomes encompassed by copy
gains, NS genomes had a larger fraction affected by DNA losses
than smokers (Student’s t-test, p=0.02) (Table 2). To address the
possible influences of the mutation and ethnic imbalances in our
cohort, PGA in EGFR mutants (n=17) versus EGFR wild-types
(n=13) and Asians (n=21) versus non-Asians (n=9) in NS tumors
only were compared. There was no significant difference in PGA
between mutant and wild-type EGFR NS tumors (Student’s t-test,
p=0.21). There was also no significant difference in PGA in Asian
versus non-Asian NS tumors (Student’s t-test, p=0.06).
Smoking status is the most strongly associated clinical
variable with observed PGA
To further determine whether the observed genome differences
were associated with clinical parameters other than smoking status
and to account for the ethnic bias in our cohort, we investigated
the PGA in tumors as a function of all clinical and genetic
variables available for our BCCA tumors (stage, gender, age,
smoking history, race, and EGFR and KRAS mutation status). A
multivariate analysis revealed that smoking status explained the
greatest amount of variance observed in PGA (multifactor
ANOVA, F=3.64, p=0.06) compared to all other factors,
followed by EGFR mutation (F=2.49, p=0.12) (Table S4). Since
NS tumors often harbor EGFR mutations this finding was not
surprising. We also performed a multivariate analysis in NS
tumors only, and found that EGFR mutations explained the
greatest amount of variance in the NS tumors alone (multifactor
ANOVA, F=3.22, p=0.09) (Table S5), although it was less
significant than the association of smoking status and PGA in the
entire tumor dataset.
PGA is greater in NS than smokers in additional cohorts
of lung adenocarcinoma
To verify our observations were not limited to the BCCA
tumors alone, we investigated publically available data for smoker
Figure 1. EGFR and KRAS mutation frequencies and PGA in the BCCA and MSKCC tumors. In both the BCCA (n=69) and MSKCC (n=66)
datasets, EGFR and KRAS mutations are more prevalent in NS and smokers, respectively, consistent with the literature (A, B). The PGA in NS was
greater than that of smokers in the BCCA and MSKCC tumors (C, D). PGA was also greater in EGFR-mutant versus EGFR-wild type tumors in both
datasets (E,F), corroborating the difference we identified in smoker and NS tumors, as NS tumors are enriched for EGFR mutations.
doi:10.1371/journal.pone.0033003.g001
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respectively [20,22]. Genomic profiling in these studies was
performed using aCGH (MSKCC) and SNP arrays (TSP). Thus,
we employed platform-appropriate methodologies to generate
copy number profiles for each tumor. In the MSKCC dataset, for
which EGFR and KRAS mutation frequencies were consistent with
smoking status classifications, we observed the same global pattern
of CNAs; NS had greater PGA than smokers (Student’s t-test,
p=4 610
23), validating our findings (Figure 1d). NS tumor
genomes had a larger fraction affected by DNA gains (Student’s
t-test, p=0.01) and DNA losses (Student’s t-test, p=0.01) than
smokers. EGFR mutant tumors also exhibited greater PGA than
EGFR wild-type tumors (Student’s t-test, p=3610
24), consistent
with our observations in the BCCA tumors.
We also interrogated the TSP dataset as an additional validation
cohort of lung adenocarcinomas from smokers and NS, albeit
acknowledging we were unable to confirm smoking histories with
mutation information. Although it did not meet statistical
Figure 2. Genomic landscapes of the BCCA NS and smoker lung adenocarcinomas. The frequency of copy number alterations throughout
the genome is depicted for smokers (A) and NS (B) tumors. Frequencies were calculated using a moving average window size of 500 SNP array
probes. Each vertical box represents a single chromosome with the hashed line indicating the centromere. The genomic locations of the differentially
altered regions (n=313) identified in the BCCA tumors are indicated in plot C. Red bars indicate NS-specific regions and blue bars indicate smoker-
specific regions.
doi:10.1371/journal.pone.0033003.g002
Table 2. Proportion of genome altered in smokers and never smokers.
PGA Type Measure Combined Smokers Never Smokers
Copy Gains Average 0.19 0.17 0.21
Median 0.19 0.17 0.22
Range 0.02–0.36 0.03–0.35 0.02–0.36
Copy Losses Average 0.17 0.15 0.20
Median 0.16 0.14 0.20
Range 0–0.43 0–0.32 0–0.43
All Copy Number Alterations Average 0.36 0.32 0.41
Median 0.37 0.29 0.41
Range 0.02–0.72 0.03–0.66 0.02–0.72
doi:10.1371/journal.pone.0033003.t002
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smokers (Student’s t-test, p=0.13) (Figure S1). The reproducibility
of our results in two additional datasets that were derived using
different genomic profiling platforms, from independent research
centers is evidence for our finding that large scale differences in
genomic landscapes exist between smoker and NS tumors.
Moreover, consistent with our results, EGFR mutations were also
associated with higher PGA (Figures 1e–f), which was expected
given that NS lung tumors and EGFR mutations are highly
correlated.
Genomic alterations common to smokers and NS
We observed that overall, the global distribution of copy
number events identified in smokers and NS in our cohort were
similar and consistent with those previously described in the
literature [6,7,8,20,22,23,24]. For example, recurrent copy
number gains on chromosomes 1q, 5p, 7p, 8q and 17q were
prominent in both groups (frequency .30% in smokers and NS)
and included known oncogenes such as ARNT, TERT, EGFR,
MYC, and ERBB2 (Figure 3). We observed concurrent mutation
and copy number gains of EGFR in 10 of 17 NS with EGFR
mutation and in the one smoker with an EGFR mutation,
consistent with previous reports of mutation accompanied by
DNA amplification [25]. However, there was no significant
difference in the occurrence of EGFR copy number gains in
EGFR mutant versus wild-type tumors (Fisher’s Exact test,
p=0.17). Common regions of copy number loss (frequency
.20% in both groups) included chromosomes 3p, 6q, 8p, 9p,
17p and 19p, and encompassed known tumor suppressors
including FHIT, CDKN2A, TP53, and LKB1 (Figure 3). A Fisher’s
Exact test to compare alteration frequencies of these known genes
in smokers and NS revealed that none were significantly different
between the two groups. The similarity in disruption to common
lung adenocarcinoma genes in smokers and NS highlights the
need to identify novel genomic aberrations that underlie the
distinct clinical phenotypes exhibited by smokers and NS.
High-level DNA alteration patterns in smokers and NS
We next sought to determine whether the high-level DNA
alteration profiles of smokers and NS differed. We used the
GISTIC algorithm to identify significant regions of focal DNA
amplification and deletion [19]. Using this approach we identified
107 events in smokers and 50 events in NS (Tables S6 and S7,
respectively). These findings suggest that although NS have a
greater PGA, the lung tumor genomes of smokers harbor more
high-level DNA alterations than NS. A total of 27 regions
overlapped in smokers and NS. Of these, 13 were altered in the
same direction (amplifications at 5p15.32, 7q11.21, 8p11.1, and
19q12; and deletions at 3p12.3, 5q31.3, 6q12, 6q16.1, 9p21.3,
10q21.1, 11q14.3, 19q12, and 22q13.31) while 14 were altered in
opposite directions in smokers and NS (7q11.21, 8p11.1, 19q12,
2q33.3, 5q31.3, 7p15.2, 8p23.3, 8q24.3, 9p21.3, 9q33.3, 10q21.1,
16q24.1, 18q23,19q12). Some regions were large enough that two
individual regions in tumors with the opposite smoking status
mapped within them, producing both same and opposite direction
alterations for some cytobands (7q11.21, 8p11.1, 19q12, 5q31.3,
9p21.3, 10q21.1 and 19q12). High-level DNA amplifications at
5p15.32 and 19q12 and deletion at 9p21.3 have been reported in
lung adenocarcinoma previously [22]. The remaining alterations
identified were specific to smokers or NS (Tables S6 and S7).
Differentially altered regions between NS and smoker
lung tumor genomes
In addition to observing a global difference in PGA between NS
and smokers and differences in high-level alteration profiles,
several genomic regions were found to have different alteration
frequencies between the groups. For example, copy number gains
of chromosome 1q were more frequent in smokers, while gains on
5q, 7p, 16p and chromosome X were more frequent in NS
(Figure 2). Additionally, chromosome 3p, 8p, 13q, 17p and 19q
losses were more prevalent in NS. To investigate these regions
using a statistical approach, we collapsed the smoker and NS
genomes into discrete regions and compared the frequencies of
alteration. We identified 313 genomic regions spanning chromo-
somes 1–22 and chromosome X that met our criteria for
differential alteration status in the BCCA tumors. These regions
included both gains and losses specific to NS and smokers.
Concordance of differentially altered regions across
multiple cohorts
To identify regions of concordance across multiple datasets, we
looked for differentially altered regions in the MSKCC tumors
that overlapped with those identified in our BCCA dataset. Of the
68 regions that were differentially altered in the MSKCC data set
between smokers and NS, our analysis revealed 21 distinct regions,
spanning 9 different chromosomes that overlapped with those
identified in our BCCA tumors. Three regions, all copy number
gains on chromosome 1q, were specific to smokers while the
remaining 18 regions included 9 copy number gains and 9 copy
number losses, were specific to NS. The discrepancy in number of
regions identified within each dataset is likely due to the higher
resolution and better detection ability of the SNP array platform
used for the BCCA analysis. Nevertheless, validation of the BCCA
regions in an external dataset with well documented smoking
histories demonstrates that in addition to exhibiting global
Figure 3. Genes commonly disrupted in smokers and NS.
Frequencies of copy number alteration for 9 genes commonly reported
as disrupted in lung adenocarcinoma are shown. The difference in
frequencies of alteration in smokers and NS was not statistically
different for any of these genes, suggesting they are equally important
in lung adenocarcinoma tumorigenesis in both smokers and NS. Fisher’s
exact test p-values for the comparison of alteration frequencies in NS
and smokers are indicated for each gene.
doi:10.1371/journal.pone.0033003.g003
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regional genomic differences as well. A list of the minimal common
regions (MCRs) of differential alteration shared by the BCCA and
MSKCC lung tumors is provided in Table 3.
We also applied this comparison to an additional cohort (TSP)
to identify the most prominent differentially altered regions
between NS and smokers in the combined datasets acknowledging
that this stringent criteria may increase the number of false-
negative regions. This analysis revealed six MCRs concordant in
all three independent datasets. All of these regions were copy
number gains specific to NS, and included two regions on
chromosome 5q, three regions on chromosome 7p, and one region
on chromosome 16p, which encompassed a total of 13 genes
(Table 4, Figure S2). The smallest MCR defined was the region at
5q33.3 which was 179 kbp in size, while the largest MCR defined
was 16p13.3-13.2 which was 3.6 Mbp. Interestingly, the frequency
of copy number gains at 5q33.3 and 5q34 in smokers was zero in
every dataset. Gains on chromosome 7p (7p14.1 and 7p12.3) were
on average 20% greater in NS than in smokers across the three
datasets, as were gains at 16p13.3-13.2. The NS-associated lung
cancer oncogene EGFR did not map to the MCRs on chromosome
7p; however, we observed a significant association between both
7p12.3 DNA gains and EGFR gains and mutations (Fisher’s Exact
test, p=0.002 and p=0.010). This finding is consistent with the
fact that EGFR function can be influenced by multiple genetic
mechanisms.
Assessing co-occurrence of identified MCRs
To assess whether the MCRs identified were independent
events within our tumors, we sought to investigate whether any of
the MCRs we identified were correlated with one another in the
BCCA tumors (Table S8). Employing a Pearson’s correlation
analysis, we discovered that the three regions located on
chromosome 7p were highly correlated (Pearson’s r .0.78). The
region on 7p14.1 was 4.7 Mbp telomeric of the first 7p12.3 region
which itself was 1.6 Mbp telomeric of the second 7p12.3 region.
We also observed a positive correlation between the 5q33.3 and
5q34 regions, which were located 4.2 Mbp from each other
(Pearson’s r=0.64). The proximity of these intrachromosomal
alterations likely contributes to the correlations observed, and
these correlations indicate that the alterations on 7p may not be
independent DNA gain events and likewise for the alterations on
5q; the alterations detected may actually represent one copy
number gain event spanning a contiguous region involving each of
the individual alterations. In addition to these intra-chromosomal
associations, we discovered a positive inter-chromosomal correla-
tion between the 5q33.3 and 16p13.3-13.2 regions (Pearson’s
r=0.52), suggesting these regions are gained concurrently in some
tumors.
Multivariate analysis assessing associations of clinical
features with MCRs
We next asked whether any of the MCRs we identified could
explain the variance in PGA that we observed. None of the six
MCRs contributed significantly to the observed PGA across the
BCCA tumor dataset. Lastly, although we identified these regions
by comparing smokers and NS, we performed a multivariate
analysis to confirm that smoking status was the factor most
strongly linked with each of the MCRs we identified. As discussed,
given the highly pronounced association between EGFR mutations
and smoking status, we expected to see that smoking history and
EGFR mutation would account for the greatest amount of variance
Table 3. Minimal common regions of differential alteration
between smokers and never smokers in BCCA and MSKCC
datasets.
Region Cytoband Chr Start End Size Status
R1 1q21.1 1 143628352 143921538 293186 Gain in Smokers
R2 1q21.1 1 146866582 146938873 72291 Gain in Smokers
R3 1q21.3 1 149678259 151582433 1904174 Gain in Smokers
R4 5q33.3 5 158495214 158674554 179340 Gain in NS
R5 5q34 5 162876149 165700950 2824801 Gain in NS
R6 7p21.2 7 13416032 13719486 303454 Gain in NS
R7 7p15.3-p15.2 7 24876559 25666836 790277 Gain in NS
R8 7p14.1 7 40005232 41936324 1931092 Gain in NS
R9 7p12.3 7 46603499 46892619 289120 Gain in NS
R10 7p12.3 7 48447956 49667305 1219349 Gain in NS
R11 8p23.1 8 9933149 10550456 617307 Loss in NS
R12 8p21.2 8 25009640 25349074 339434 Loss in NS
R13 8p21.1 8 28103525 29457984 1354459 Loss in NS
R14 8p12 8 38180851 38440527 259676 Loss in NS
R15 9q33.2 9 122816481 122966826 150345 Loss in NS
R16 10q11.21 10 42955951 43010057 54106 Loss in NS
R17 13q12.11 13 18601703 18653178 51475 Loss in NS
R18 16p13.3-p13.2 16 5278276 8866443 3588167 Gain in NS
R19 16p12.1-p11.2 16 27313417 27917742 604325 Gain in NS
R20 18q21.2 18 46480704 46480763 59 Loss in NS
R21 18q22.3 18 69959421 69976724 17303 Loss in NS
doi:10.1371/journal.pone.0033003.t003
Table 4. Minimal common regions of differential alteration between smokers and never smokers in three independent datasets.
Region Cytoband Chr Start End Size Status Genes in MCR
Region 1 5q33.3 5 158495214 158674554 179340 Gain NS IL12B, RNF145, UBLCP1
Region 2 5q34 5 162876149 165700950 2824801 Gain NS MAT2B
Region 3 7p14.1 7 40455608 41936324 1480716 Gain NS C7ORF10, INHBA
Region 4 7p12.3 7 46603499 46892619 289120 Gain NS -
Region 5 7p12.3 7 48447956 49667305 1219349 Gain NS ABCA13
Region 6 16p13.3-13.2 16 5278276 8866443 3588167 Gain NS A2BP1, ABAT, C16ORF68, CARHSP1,
PMM2, TMEM186
doi:10.1371/journal.pone.0033003.t004
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most strongly associated with all of the regions we discovered,
except for 7p14.1, for which the factor explaining the greatest
amount of variance was age (followed closely by EGFR mutation).
Discussion
Given the enormous efforts put forth to promote smoking
cessation and prevention initiatives, in the next few decades NS
(and former smokers) will constitute a larger proportion of the lung
cancer population [2]. It is a well established concept that lung
tumors in smokers and NS are distinct disease entities [2,3,26,27].
At the DNA level, molecular differences discovered to date are
gene-specific and cannot account for all of the clinical differences
exhibited by smokers and NS [2,3,26]. In this study we sought to
elucidate global genomic differences in lung adenocarcinomas
from NS and smokers. Using a genome-wide comparison
approach, we discovered that NS lung tumors have a greater
proportion of their genomes altered than those of smokers, we
identified regional genomic disparities in the tumor genomes of
these two groups, and we validated our findings in two
independent external cohorts from the Memorial Sloan Kettering
Cancer Centre (MSKCC) and Tumor Sequencing Project (TSP).
EGFR and KRAS mutations in the BCCA and MSKCC tumors
segregated with NS and smokers, respectively, consistent with the
reported literature. This confirmed the accuracy of our smoking
status classifications and validated that these tumors were
appropriate to perform a smoker versus NS genome comparison.
Genes and regions known to be frequently disrupted in lung
adenocarcinoma were not preferentially disrupted in smokers or
NS, and the recurrent alterations we observed in both groups were
highly concordant with recent reports [6,7,8,20,22,23,24]. For
example, the most frequently altered region detected in our 69
tumors was gain of 5p15.32-15.33 (51% of tumors), which harbors
the hallmark cancer gene TERT. Gain of 5p was also the most
common genomic alteration observed by Weir et al. in a collection
of over 350 lung adenocarcinoma tumors [22]. Having established
that regions commonly altered in lung adenocarcinoma were not
associated with smoking status, we proceeded to determine
whether distinct genomic features exist that may underlie the
disparate clinical phenotypes observed in smoker and NS lung
cancer patients.
Intriguingly, our comparative study revealed that NS lung
tumors have a greater fraction of the genome encompassed by
genomic alterations. Despite the caveat that our smoker and NS
groups were not balanced for ethnicity or mutation (which is not
surprising given the known clinical and molecular features
associated with smoking status) our multivariate analysis suggested
smoking history was the clinical variable most strongly associated
with this observed difference. However, since an earlier study that
sampled a small fraction of the genome had suggested a greater
degree of alterations in smoker tumors [8], we assessed the
repeatability of our results in two additional independent cohorts.
Specifically we investigated whether the observed global genomic
distinction in NS tumors was also evident in these two independent
cohorts (MSKCC and TSP, from distant geographical sites, with
likely different demographics). Across these three independently
performed genomic analyses, we found corroborating results. Even
though our observation held true in independent datasets, we are
mindful of the fact that the contributions of mutational and
smoking status cannot be distinguished in our study. It remains a
possibility that PGA is associated with mutation, as PGA between
NS and smokers with no mutations was not significantly different.
Our study is not powered to test adjusted effects of smoking or
mutation type on PGA adjusting for all other confounding factors.
This is because smoking and race are correlated with EGFR or
KRAS mutation. A clean comparison would require large numbers
of patients in each smoking/mutation/race combination, at least
300 subjects for each, in order to achieve 80% power to detect a
10% difference in PGA at a significance level of 0.05.
Amidst the genomic instability observed in the lung adenocar-
cinoma tumors, we identified frequent genomic alterations whose
recurrent nature signifies their selection in tumor genomes. After
cataloguing numerous differentially altered regions in our dataset,
we interrogated two independent cohorts to validate our findings
and to reveal the most robust and pronounced regional differences
in smokers and NS. We identified six MCRs of copy number gain
on chromosomes 5q, 7p and 16p. It is possible that additional, less
prominent MCRs, may have been identified had we used less
stringent concordance criteria between the three datasets. The
regions we have reported are the most robust as they are present in
multiple independent cohorts. Again, we performed a multivariate
analysis to confirm that smoking status (and subsequently EGFR
mutation) was the strongest factor associated with genomic regions
of difference identified. Broet et al. recently reported regions
differentially altered in East-Asian and Western European lung
adenocarcinoma tumors, none of which overlapped with the
smoking-related regions we identified, indicating that our regions
are not ethnic specific [6]. The two MCRs we identified on 5q
were strongly correlated with one another, as were the three
MCRs on 7p, suggesting they may actually be the result of single
copy number events. The positive correlation we observed
between 5q and 16p could signify that concurrent gains of these
regions is non-random and may be biologically relevant.
A recent study profiled 60 NS lung adenocarcinomas using
array comparative genomic hybridization (aCGH), albeit without
a comparison against tumors from smokers, reporting several
MCRs of copy number gain and loss [7]. We cross referenced our
differentially altered regions to the regions identified by Job et al. to
determine whether any of their regions might be NS-specific. Most
of the regions reported by Job et al. were commonly disrupted in
NS and smokers in our BCCA tumors; however, Job et al. also
reported regions of copy number gain on chromosomes 5q, 7p and
16p which we identified as NS-specific. Both of our groups
observed gains of chromosome 1q21 in NS, however in our
cohort, 1q21.1 gain was up to 30% more frequent in smokers than
NS, suggesting it may be a smoker-specific alteration.
Early profiling studies led to the discovery that gains of
chromosome 16p are more common in NS than smokers, and
this remains one of the few consistently replicated NS-specific
genetic alterations discovered to date, which implicates the
importance of this region in NS tumor biology [2,3,6,7,26]. We
and others also observed an association between gain of 16p13.3-
13.2 and Asian ethnicity, however, this could reflect the fact that a
large fraction of NS lung cancer patients are of Asian descent
[2,6]. The earliest NS lung tumor profiling studies did not identify
frequent gains of 5q in NS; however, we found two robust regions
of gain at 5q33.3 and 5q34. Other recent studies have also
identified frequent gains on 5q in NS lung adenocarcinomas,
corroborating our results [6,7,8].
Our analysis revealed three distinct MCRs of gain on 7p,
however none encompassed the lung cancer oncogene, EGFR,
located on chromosome 7p11.2. The closest region (7p12.3) was
situated 5.4 Mbp telomeric of the EGFR locus. The presence of
these MCRs could imply that additional oncogenes are responsible
for 7p gains, as previously suggested [28]. Investigators from the
MSKCC discovered that DUSP4, a gene located on chromosome
8p12, was down regulated and associated with EGFR mutation
Lung Cancer Differs in Smokers and Never Smokers
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this association (Fisher’s Exact test, p=0.05). Interestingly, we also
mapped an MCR of loss on 8p in the BCCA and MSKCC
datasets which encompassed DUSP4 and found that this region
was more frequently lost in NS tumors. Although 8p was not one
of our most robust differentially altered regions, it appears
genomic loss of DUSP4 is associated with EGFR mutation and NS.
While many known regions of copy number alteration in lung
adenocarcinoma were present in both our smoker and NS cohorts,
our results, along with the well established differences in mutational
profilesandclinical features, suggest lung tumorsof smokersandNS
develop through different molecular mechanisms. This may be
similar to what has been observed in ovarian cancer, where Type I
serous ovarian cancers are typically chromosomally stable and
harbor mutations in the Ras signaling pathway, while high-grade
serous ovarian cancers (Type II) are RAS wild-type and exhibit
widespread copy number aberrations [29]. Intriguingly, Sidransky
and co-workers recently discovered that NS lung adenocarcinoma
genomes have a greater number of mitochondrial DNA alterations
than smokers [9]. This finding is consistent with our discovery,
providing additional evidence to support the concept that lung
cancers in smokers and NS are driven by different molecular
alterations. We postulate that NS lung tumors acquire specific
genetic alterations early in tumorigenesis that compromise genome
integrity. For example, we hypothesize that NS could be inherently
predisposed to genomic instability, or they could be exposed to non-
tobacco related carcinogens that drive genomic instability. Eluci-
dation of the precise mechanism driving this instability phenotype
could potentially lead to targeted therapy for NS patients, or to
identify NS at risk of lung cancer development.
It is well known that the mutation profile of NS lung
adenocarcinoma is distinct from that of smokers [2]. The recent
discovery of increased mtDNA mutations and mtDNA content in
NS relative to smokers further supports the concept that the
distinction between smoker and NS tumors extends beyond EGFR
and KRAS mutations [9]. Our findings provide a third and novel
line of evidence towards genetic differences between smoker and
NS lung tumors, namely, that the extent of segmental genomic
alterations is greater in NS tumors. Collectively, our findings
provide evidence that these lung tumors are globally and
genetically different, which implies they are likely driven by
distinct molecular mechanisms. Although the biological mecha-
nism underlying our observations in NS remains unknown,
elucidation of this mechanism is crucial to the early detection
and possibly treatment of these patients, as no known risk factors
or molecular features exist to assess lung cancer risk in NS besides
family history. Our work provides a rationale for the stratification
of patients based on smoking status in future studies, which will in
turn facilitate discoveries of the nature of lung cancer in both
smokers and NS. Prospective findings will have significant
implications and may lead to the development of clinical tools
that could be utilized to improve the prognosis of both smoker and
NS patients.
Supporting Information
Figure S1 PGA in smokers and NS in the TSP dataset.
Although it did not meet statistical significance, NS lung tumors
have greater PGA than smoker lung tumors on average.
(TIF)
Figure S2 Six minimal common regions (MCRs) of
difference between smokers and NS. The six regions
described in Table 4 are illustrated here. The region from each
dataset involved in the MCR is shown with the genomic
coordinates flanking each region (A). Hashed lines indicate the
MCR region boundaries. Regions are not drawn to scale. The
frequencies of DNA copy number gains in smoker and NS tumors
for each dataset is indicated (B). Since the differentially altered
regions in each dataset were defined by merging adjacent
significant regions into one (as described in the Methods), the
frequencies illustrated are the minimum frequencies observed for
regions contributing to the merged region. Fisher’s exact test p-
values for the comparison of alteration frequencies in NS and
smokers are indicated for each region in each dataset.
(TIF)
Table S1 Genomic DNA PCR primers. PCR on genomic
DNA was performed to determine EGFR and KRAS mutation
status in the BCCA lung tumor cohort. Mutations and primer
sequences are shown.
(DOC)
Table S2 Matrix summarizing correlations between
clinical and genetic variables in the 69 BCCA tumors.
A correlation analysis was performed to determine the associations
between different clinical and molecular factors in the BCCA lung
tumor cohort. Correlation coefficients for each pair of variables
are shown.
(DOC)
Table S3 Summary of alteration frequencies in BCCA
smoker (n=39) and NS (n=30) lung tumors. The
frequency of copy number alterations throughout the genome
(calculated using a moving average window of 500 SNP array
probes) was determined and summarized for each group (all 69
tumors, 39 smoker tumors and 30 never smoker tumors). The
minimum (Min), maximum (Max), median, and average frequen-
cies for each group are indicated. Total frequency (Gain & Loss),
frequency of gain, and frequency of loss are reported.
(DOC)
Table S4 Multifactor ANOVA test results for assessing
the effects of clinical and genetic factors on observed
PGA in 69 BCCA tumors. A multifactor ANOVA was
performed to investigate the effects of multiple factors on PGA
in the BCCA lung tumor cohort (n=69). The ANOVA test
statistics are shown.
(DOC)
Table S5 Multifactor ANOVA test results for assessing
the effects of clinical and genetic factors on observed
PGA in NS tumors only. A multifactor ANOVA was
performed to investigate the effects of multiple factors on PGA
in never smokers only (n=30). The ANOVA test statistics are
shown.
(DOC)
Table S6 High-level DNA changes in smoker lung
tumors. GISTIC was used to reveal high level DNA alterations
in 39 smoker lung tumors from the BCCA. Copy number status,
genomic location, and frequency of alteration are indicated.
(DOC)
Table S7 High-level DNA changes in NS lung tumors.
GISTIC was used to reveal high level DNA alterations in 30 never
smoker lung tumors from the BCCA. Copy number status,
genomic location, and frequency of alteration are indicated.
(DOC)
Table S8 Matrix summarizing correlations between
each minimal common region identified in the 69 BCCA
tumors. The six minimal common regions identified in the
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another. The correlation coefficients for each pair of regions are
shown.
(DOC)
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